首页> 外文期刊>Multiple Sclerosis International >Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation
【24h】

Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation

机译:多发性硬化症中的血液和CSF生物标志物动力学:数据解释的含义。

获取原文
       

摘要

Background. Disability in multiple sclerosis (MS) is related to neuroaxonal degeneration. A reliable blood biomarker for neuroaxonal degeneration is needed.Objectives. To explore the relationship between cerebrospinal fluid (CSF) and serum concentrations of a protein biomarker for neuroaxonal degeneration, the neurofilaments heavy chain (NfH).Methods. An exploratory cross-sectional (n=51) and longitudinal (n=34) study on cerebrospinal fluid (CSF) and serum NfH phosphoform levels in patients with MS. The expanded disability status scale (EDSS), CSF, and serum levels of NfH-SMI34 and NfH-SMI35 were quantified at baseline. Disability progression was assessed at 3-year followup.Results. At baseline, patients with primary progressive MS (PPMS, EDSS 6) and secondary progressive MS (SPMS, EDSS 6) were more disabled compared to patients with relapsing remitting MS (RRMS, EDSS 2,P<.0001). Serum and CSF NfH phosphoform levels were not correlated. Baseline serum levels of the NfH-SMI34 were significantly (P<.05) higher in patients with PPMS (2.05 ng/mL) compared to SPMS (0.03 ng/mL) and RRMS (1.56 ng/mL). In SPMS higher serum than CSF NfH-SMI34 levels predicted disability progression from baseline (ΔEDSS2,P<.05). In RRMS higher CSF than serum NfH-SMI35 levels predicted disability progression (ΔEDSS2,P<.05).Conclusion. Serum and CSF NfH-SMI34 and NfH-SMI35 levels did not correlate with each other in MS. The quantitative relationship of CSF and serum NfH levels suggests that neuroaxonal degeneration of the central nervous system is the likely cause for disability progression in RRMS. In more severely disabled patients with PP/SPMS, subtle pathology of the peripheral nervous system cannot be excluded as an alternative source for blood NfH levels. Therefore, the interpretation of blood protein biomarker data in diseases of the central nervous system (CNS) should consider the possibility that pathology of the peripheral nervous system (PNS) may influence the results.
机译:背景。多发性硬化症(MS)中的残疾与神经轴突变性有关。需要用于神经轴突变性的可靠的血液生物标志物。探讨脑脊液(CSF)与血清蛋白标记物对神经轴索变性(神经丝重链(NfH))的关系。探索性横断面(n = 51)和纵向(n = 34)对MS患者的脑脊液(CSF)和血清NfH磷酸化水平的研究。在基线时对扩大的残疾状态量表(EDSS),CSF和NfH-SMI34和NfH-SMI35的血清水平进行定量。在3年的随访中评估了残疾的进展。在基线时,与复发缓解型MS(RRMS,EDSS 2,P <.0001)的患者相比,原发性进行性MS(PPMS,EDSS 6)和继发性进行性MS(SPMS,EDSS 6)患者更易失能。血清和脑脊液NfH磷酸化水平无关。与SPMS(0.03μng/ mL)和RRMS(1.56μng/ mL)相比,PPMS(2.05μng/ mL)患者的NfH-SMI34基线血清水平显着更高(P <.05)。在SPMS中,血清中CSF NfH-SMI34的水平高于基线,预示了残疾将从基线发展(ΔEDSS2,P <.05)。在RRMS中CSF高于血清NfH-SMI35水平可预测残疾进展(ΔEDSS2,P <.05)。血清和脑脊液NfH-SMI34和NfH-SMI35水平在MS中不相关。脑脊液和血清NfH水平的定量关系表明,中枢神经系统的神经轴突变性可能是RRMS残疾进展的原因。在PP / SPMS更严重残疾的患者中,不能排除周围神经系统的细微病理作为血液NfH水平的替代来源。因此,在中枢神经系统(CNS)疾病中血液蛋白生物标志物数据的解释应考虑外周神经系统(PNS)病理可能影响结果的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号